PBE concentrates on 31 companies and offers a higher dividend yield, while IBBQ spreads risk across 251 holdings at a ...

These biotech stocks all popped after their recent earnings reports. All three have outperformed 97% of stocks in the last 12 ...

Werewolf Therapeutics, Inc. HOWL was one of the market’s biggest pre-market movers on Friday after announcing a merger with ...

Chief Market Strategist at SlateStone Wealth, Llc Kenny Polcari joins Stuart Varney to discuss Bitcoin’s rally, Moderna’s ...

Harlan Robins spent years as the co-founder and chief scientific officer of Adaptive Biotechnologies, helping build massive datasets to decode… Read More ...

VanEck's concentrated 25-stock biotech play offers higher volatility, while iShares' broader pharma exposure delivered a 1.4% ...

Franklin Biotechnology Discovery has a much higher 13% five-year annualized return than a biotech index ETF’s 5.3% ...

Virtus Biotech ETF (BBP) gets a buy rating: equal-weight, quarterly rebalanced exposure to FDA-approved biotechs, deal ...

Scribe Therapeutics’ one-time epigenetic treatment is designed to slash the adherence burden of chronic cholesterol-lowering ...

Biotech stocks are considered extremely high-risk, high-reward investments. Many biotech companies are developing one or more ...

The drugmaker should significantly mitigate its most important risk as it develops new products.

A Pittsburgh biotech company appears to be setting up financial success by pivoting to provide compute for AI companies.